

Benchmark crude oil prices have corrected ~15% over the last 15 days to ~USD65-70/bbl (WTI-Brent), led by macro weakness on account of nearing OPEC+ production ramp-up, weak Chinese demand outlook, and muted US economic data. Benchmark refining margins are also down to low-single digit. Chinese oil demand is perceived to be affected by a weak domestic scenario and shift to alternates. US oil demand seems reasonable while Indian crude demand is fairly stable at 3-4% YoY growth in CY24TD. We believe near-term volatility could persist in oil prices with tapering of OPEC+ production cut being a major bearish factor, although demand environment can be supported by lower pump prices, strategic restocking, and a global interest rate cut cycle. Nevertheless, we believe Brent could de-rate to a USD70-80/bbl range from a USD80-90/bbl range earlier. Consequently, our average Brent assumption for FY25E/26E/27E could be down from USD85/bbl each to USD80/75/75, though we have kept it unchanged for now.

Indian Oil & Gas sector sees a mixed impact from lower oil prices with upstream, petchem, and gas sector being affected negatively from lower realizations, deltas, and adverse economics, whereas oil downstream and retailing and lubes should gain from better margins and volumes (if prices are cut). However, against a USD70/bbl Brent, upstream stock (ONGC and Oil India) correction of ~15% during this period seems excessive, given that they were earning only USD75/bbl due to windfall taxes. Hence, we retain our estimates and even at USD70/bbl Brent, SA (standalone) EPS cut would be 6-9%, therefore vs CMP we remain constructive, maintaining our BUY ratings on ONGC and OIL. For OIL, a USD2/bbl drop in NRL's book GRM results in a 2% annual decline in its consolidated EPS.

We believe there are expectations of a retail price cut in auto-fuels for OMCs (IOCL, BPCL, and HPCL) amid the upcoming state elections. While we do not rule out the same, the model code of conduct for J&K and Haryana is on for a month. There could be a cut only toward Diwali and before Maharashtra election's model code of conduct, which could be Rs2/ltr each for petrol and diesel and possibly coupled with an equivalent increase in excise duty. However, during the next one month OMCs can earn supernormal marketing margins, covering LPG under-recoveries and inventory losses to a large extent. We estimate implied Q2FY25E gross marketing margins at Rs9.7/8 per liter for petrol/diesel vs Rs4.7/3.8 in Q1 and a normative range of Rs3.5-4 each.

USD75/bbl Brent in H2FY25, and a Rs4/ltr margin impact from price cuts and excise hikes could still yield Rs5-7/ltr of margins, which is healthy. Based on current Aramco contract prices, system-level LPG under-recoveries could amount to ~Rs300bn by FY25-end, though being a controlled item, a one-time subsidy from GoI is also expected. While Aramco propane-butane for September is steady, futures leading up to Mar-25 is indicating a steady decline given the lower oil prices offsetting seasonality. We reiterate our BUY rating on HPCL, BPCL, and IOCL. While BPCL is fundamentally the strongest, HPCL's Vizag expansion and modernization project is expected to fully complete this month, and from Q3FY25 GRM uptick can be seen if stabilization is successfully completed. IOCL stock has relatively underperformed HPCL and BPCL recently, but it does have a higher inventory loss risk.

**Sabri Hazarika**

sabri.hazarika@emkayglobal.com  
+91 22 6612 1282

**Harsh Maru**

harsh.maru@emkayglobal.com  
+91 22 6612 1336


**Arya Patel**

arya.patel@emkayglobal.com  
+91 22 6612 1285


### Rating, Target Price and Valuation

Standalone	Rating	CMP	TP	Upside	EV/EBITDA (x)		P/E (x)	
		(Rs/sh)	(Rs/sh)	(%)	FY25E	FY26E	FY25E	FY26E
Indian Oil	ADD	170	205	21	7.0	6.7	10.3	10.6
BPCL	BUY	340	405	19	6.5	6.5	9.8	8.9
HPCL	BUY	409	475	16	8.1	6.7	11.2	9.3
ONGC	BUY	285	360	26	5.0	4.7	9.1	9.1
Oil India	BUY	583	700	20	8.2	8.1	10.3	10.2


Source: Company, Emkay Research

**Exhibit 1: China's oil demand affected by weak domestic scenario**


Source: Bloomberg, Emkay Research

**Exhibit 2: US crude oil demand reasonable and largely flattish**


Source: EIA, Bloomberg, Emkay Research

**Exhibit 3: Indian crude oil demand growing steadily**


Source: PPAC, Bloomberg, Emkay Research

**Exhibit 4: Current GRMs imply weak trend for OMCs in the near term (including inventory losses)**


Source: Company, Bloomberg, Emkay Research

**Exhibit 5: Strong auto-fuel marketing margins currently; LPG losses high but can reduce**


Source: Company, Bloomberg, Emkay Research

**Exhibit 6: EBITDA profile across OMCs should improve considerably in Q2 and H2FY25E vs Q1**

Source: Company, Emkay Research; Note – Based on USD75 Brent and Rs2/ltr cut in auto-fuel RSP each

**Exhibit 7: Estimated LPG under-recoveries across OMCs in FY25E**

Source: Company, Emkay Research

**Exhibit 8: Propane futures show gradual decline hereon till fiscal end**

Source: CME, Emkay Research

**Exhibit 9: Upstream - EPS Sensitivity to oil prices**

<b>FY26E - Brent (USD/bbl)</b>	<b>60</b>	<b>65</b>	<b>70</b>	<b>75</b>	<b>80</b>
ONGC SA EPS (Rs)	22	27	30	32	32
Change	-16%	-10%	-9%	1%	
OIL SA EPS (Rs)	39	44	49	53	52
Change	-12%	-10%	-7%	2%	
ONGC Consol. EPS (Rs)	33	38	41	45	45
Change	-13%	-8%	-8%	0%	
OIL Consol. EPS (Rs)	48	53	58	62	61
Change	-10%	-8%	-6%	1%	

Source: Emkay Research

**Exhibit 10: OIL's consolidated EPS sensitivity to NRL's Book GRM**

<b>FY26E - NRL Book GRM (USD/bbl)</b>	<b>20</b>	<b>22</b>	<b>24</b>	<b>26</b>	<b>28</b>
NRL PAT (Rs mn)	11,174	13,926	16,678	19,430	22,183
OIL's consol. EPS (Rs)	58	59	60	62	63
Change	-2%	-2%	-2%	-2%	

Source: Emkay Research

**Exhibit 11: Upstream - EPS and TP impact from change in oil prices**

<b>FY26E - Brent (USD/bbl)</b>	<b>60</b>	<b>65</b>	<b>70</b>	<b>75</b>	<b>80</b>	<b>85</b>
ONGC Consol. EPS (Rs)	34	38	41	45	45	44
ONGC Target P/E (x)	8	8	8	8	8	8
ONGC Implied TP (Rs/sh)	281	309	337	365	366	360
OIL Consol. EPS (Rs)	48	53	58	62	61	60
OIL Target P/E (x)	12	12	12	12	12	12
OIL Implied TP (Rs/sh)	556	620	678	719	710	700

Source: Emkay Research


## INDIAN OIL

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
20-Aug-24	172	205	Add	Sabri Hazarika
30-Jul-24	183	205	Add	Sabri Hazarika
01-May-24	169	180	Add	Sabri Hazarika
15-Mar-24	161	160	Add	Sabri Hazarika
20-Feb-24	189	160	Add	Sabri Hazarika
25-Jan-24	144	160	Add	Sabri Hazarika
09-Dec-23	119	135	Add	Sabri Hazarika
30-Nov-23	112	120	Add	Sabri Hazarika
24-Nov-23	103	120	Buy	Sabri Hazarika
01-Nov-23	92	100	Hold	Sabri Hazarika
28-Jul-23	95	100	Hold	Sabri Hazarika
17-May-23	88	100	Buy	Sabri Hazarika
01-Feb-23	80	90	Buy	Sabri Hazarika
06-Dec-22	76	85	Buy	Sabri Hazarika
29-Oct-22	68	85	Buy	Sabri Hazarika
07-Sep-22	71	90	Buy	Sabri Hazarika
31-Jul-22	73	90	Buy	Sabri Hazarika
15-Jul-22	70	140	Buy	Sabri Hazarika
28-Jun-22	72	140	Buy	Sabri Hazarika
22-May-22	78	140	Buy	Sabri Hazarika
17-May-22	83	140	Buy	Sabri Hazarika
09-Mar-22	78	155	Buy	Sabri Hazarika
03-Feb-22	83	160	Buy	Sabri Hazarika
25-Dec-21	74	150	Buy	Sabri Hazarika
23-Nov-21	84	150	Buy	Sabri Hazarika
02-Nov-21	87	150	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research


## BPCL

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
20-Aug-24	349	405	Buy	Sabri Hazarika
21-Jul-24	304	370	Buy	Sabri Hazarika
10-May-24	309	365	Buy	Sabri Hazarika
15-Mar-24	293	300	Buy	Sabri Hazarika
20-Feb-24	329	300	Buy	Sabri Hazarika
30-Jan-24	252	300	Buy	Sabri Hazarika
09-Dec-23	235	273	Buy	Sabri Hazarika
30-Nov-23	218	250	Add	Sabri Hazarika
24-Nov-23	205	250	Buy	Sabri Hazarika
31-Oct-23	175	210	Buy	Sabri Hazarika
27-Jul-23	190	198	Hold	Sabri Hazarika
23-May-23	183	198	Hold	Sabri Hazarika
31-Jan-23	172	175	Hold	Sabri Hazarika
06-Dec-22	164	175	Hold	Sabri Hazarika
08-Nov-22	155	175	Hold	Sabri Hazarika
07-Sep-22	163	188	Hold	Sabri Hazarika
07-Aug-22	168	188	Hold	Sabri Hazarika
15-Jul-22	156	208	Buy	Sabri Hazarika
28-Jun-22	159	208	Buy	Sabri Hazarika
26-May-22	162	208	Buy	Sabri Hazarika
22-May-22	166	230	Buy	Sabri Hazarika
09-Mar-22	171	230	Buy	Sabri Hazarika
02-Feb-22	191	258	Buy	Sabri Hazarika
25-Dec-21	186	255	Buy	Sabri Hazarika
23-Nov-21	199	255	Buy	Sabri Hazarika
31-Oct-21	209	255	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research


## HPCL

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
20-Aug-24	397	475	Buy	Sabri Hazarika
30-Jul-24	396	475	Buy	Sabri Hazarika
11-May-24	334	400	Buy	Sabri Hazarika
15-Mar-24	313	333	Buy	Sabri Hazarika
20-Feb-24	375	333	Buy	Sabri Hazarika
26-Jan-24	287	333	Buy	Sabri Hazarika
09-Dec-23	252	297	Buy	Sabri Hazarika
30-Nov-23	232	267	Buy	Sabri Hazarika
24-Nov-23	213	267	Buy	Sabri Hazarika
07-Nov-23	186	203	Hold	Sabri Hazarika
03-Aug-23	180	180	Hold	Sabri Hazarika
15-May-23	173	180	Hold	Sabri Hazarika
10-Feb-23	155	153	Hold	Sabri Hazarika
06-Dec-22	149	153	Hold	Sabri Hazarika
04-Nov-22	136	153	Hold	Sabri Hazarika
07-Sep-22	163	173	Hold	Sabri Hazarika
07-Aug-22	167	173	Hold	Sabri Hazarika
15-Jul-22	160	197	Buy	Sabri Hazarika
28-Jun-22	148	197	Buy	Sabri Hazarika
22-May-22	163	197	Buy	Sabri Hazarika
21-May-22	163	197	Buy	Sabri Hazarika
09-Mar-22	179	220	Buy	Sabri Hazarika
02-Feb-22	194	240	Buy	Sabri Hazarika
25-Dec-21	194	227	Buy	Sabri Hazarika
23-Nov-21	212	227	Hold	Sabri Hazarika
03-Nov-21	209	227	Hold	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research


## ONGC

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
06-Aug-24	306	360	Buy	Sabri Hazarika
21-May-24	280	320	Buy	Sabri Hazarika
12-Feb-24	258	300	Buy	Sabri Hazarika
24-Dec-23	204	250	Buy	Sabri Hazarika
30-Nov-23	195	235	Buy	Sabri Hazarika
15-Nov-23	200	235	Buy	Sabri Hazarika
12-Aug-23	177	220	Buy	Sabri Hazarika
30-May-23	159	215	Buy	Sabri Hazarika
15-Feb-23	148	200	Buy	Sabri Hazarika
06-Dec-22	142	195	Buy	Sabri Hazarika
01-Dec-22	140	195	Buy	Sabri Hazarika
24-Nov-22	139	195	Buy	Sabri Hazarika
02-Oct-22	127	190	Buy	Sabri Hazarika
07-Sep-22	133	190	Buy	Sabri Hazarika
13-Aug-22	139	190	Buy	Sabri Hazarika
15-Jul-22	127	185	Buy	Sabri Hazarika
02-Jul-22	131	185	Buy	Sabri Hazarika
28-Jun-22	149	210	Buy	Sabri Hazarika
31-May-22	151	210	Buy	Sabri Hazarika
22-May-22	162	230	Buy	Sabri Hazarika
01-Apr-22	168	230	Buy	Sabri Hazarika
09-Mar-22	175	230	Buy	Sabri Hazarika
15-Feb-22	164	220	Buy	Sabri Hazarika
25-Dec-21	139	185	Buy	Sabri Hazarika
23-Nov-21	147	185	Buy	Sabri Hazarika
14-Nov-21	155	185	Buy	Sabri Hazarika
16-Sep-21	129	150	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research


## OIL INDIA

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
09-Aug-24	644	700	Buy	Sabri Hazarika
28-May-24	435	533	Buy	Sabri Hazarika
21-May-24	443	533	Buy	Sabri Hazarika
15-Feb-24	375	447	Buy	Sabri Hazarika
24-Dec-23	249	297	Buy	Sabri Hazarika
30-Nov-23	203	247	Buy	Sabri Hazarika
09-Nov-23	202	247	Buy	Sabri Hazarika
09-Aug-23	184	220	Buy	Sabri Hazarika
05-Jun-23	169	220	Buy	Sabri Hazarika
25-May-23	174	220	Buy	Sabri Hazarika
13-Feb-23	161	193	Buy	Sabri Hazarika
06-Dec-22	141	180	Buy	Sabri Hazarika
01-Dec-22	138	180	Buy	Sabri Hazarika
24-Nov-22	131	180	Buy	Sabri Hazarika
02-Oct-22	116	173	Buy	Sabri Hazarika
07-Sep-22	130	173	Buy	Sabri Hazarika
11-Aug-22	125	173	Buy	Sabri Hazarika
15-Jul-22	122	180	Buy	Sabri Hazarika
02-Jul-22	143	180	Buy	Sabri Hazarika
28-Jun-22	166	203	Buy	Sabri Hazarika
04-Jun-22	167	203	Buy	Sabri Hazarika
22-May-22	160	223	Buy	Sabri Hazarika
01-Apr-22	159	223	Buy	Sabri Hazarika
09-Mar-22	162	223	Buy	Sabri Hazarika
15-Feb-22	150	213	Buy	Sabri Hazarika
25-Dec-21	118	180	Buy	Sabri Hazarika
23-Nov-21	132	180	Buy	Sabri Hazarika
12-Nov-21	148	180	Buy	Sabri Hazarika
16-Sep-21	141	170	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.



**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 12, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 12, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 12, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.